EUCTR2018-001718-13-NO进行中（未招募）1 期
An Open- Label, Phase 2, Multicenter Feasibility Study if Manualized MDMA-Assisted Psychotherapy with an fMRI sub-study Assessing Changes in Brain Activity in Subjects with Posttraumatic Stress Disorder.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Are at least 18 years old
- •- Are fluent in speaking and reading the predominantly used orrecognized language of the study site
- •- Are able to swallow pills
- •- Agree to have study visits video-recorded, including ExperimentalSessions, Independent Rater assessments, and non-drug psychotherapysessions
- •- Must provide a contact (relative, spouse, close friend or other supportperson) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal or unreachable
- •- Must agree to inform the investigators within 48 hours of any medicaltreatments and procedures
- •- People able to become pregnant (PABP) (i.e.,assigned female at birth,fertile, following menarche and until becoming post-menopausal unless permanently sterile), must havea highly sensitive negative pregnancy test at study entry and prior to each Experimental Session, and must agree to use adequate birth control through 10 daysafter the last Experimental Session. Adequate birth control methods include intrauterine device (IUD), injected or implanted hormonal methods, abstinence, oral hormones plus a barrier contraception,vasectomized sole partner. Not of childbearing potential is defined as permanent sterilization or assigned male at birth.
- •- Agree to the following lifestyle modifications: comply withrequirements for fasting and refraining from certain medications prior to Experimental Sessions, not enroll in any other interventional clinicaltrials during the duration of the study, remain overnight at the study siteafter each Experimental Session and be driven home after, and commit to medication dosing, therapy, and study procedures.
- •- At Screening, meet DSM-5 criteria for current PTSD
- •- May have well-controlled hypertension that has been successfully treated with anti-hypertensive medicines, if they pass additional screening to rule out underlying cardiovascular disease
- •- May have asymptomatic Hepatitis C virus (HCV) that has previously undergone evaluation and treatment as needed.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 32
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 8
排除标准
- •- Are not able to give adequate informed consent
- •- Have any current problem which, in the opinion of the investigator orMedical Monitor, might interfere with participation
- •- Would present a serious risk to others as established through clinicalinterview and contact with treating psychiatrist
- •- Require ongoing concomitant therapy with a psychiatric medicationwith exceptions described in the protocol.
- •- Weigh less than 48 kilograms (kg)
- •- Are pregnant or nursing or are of childbearing potential and are notpracticing an effective means of birth control.
研究者
相似试验
进行中（未招募）
1 期
MDMA-Assisted Psychotherapy for the Treatment of PTSDEUCTR2018-001718-13-GBMAPS Europe B.V.40
进行中（未招募）
1 期
MDMA-Assisted Psychotherapy for the Treatment of PTSDEUCTR2018-001718-13-ESMAPS Europe B.V.40
进行中（未招募）
1 期
MDMA-Assisted Psychotherapy for the Treatment of PTSDEUCTR2018-001718-13-CZMAPS Europe B.V.40
进行中（未招募）
1 期
MDMA-Assisted Psychotherapy for the Treatment of PTSDEUCTR2018-001718-13-DEMAPS Europe B.V.40
进行中（未招募）
1 期
MDMA-Assisted Psychotherapy for the Treatment of PTSDpost-traumatic stress disorder (PTSD)EUCTR2018-001718-13-NLMAPS Europe B.V.40